

Биологически активные добавки при подагре: возможности и перспективы
https://doi.org/10.33667/2078-5631-2024-29-13-18
Аннотация
В последние годы наблюдается растущий интерес к использованию биологически активных добавок (БАД) в комплексной терапии подагры, что открывает новые горизонты для пациентов и врачей. Подагра, будучи метаболическим заболеванием, требует не только традиционных методов лекарственной терапии, но и дополнительных стратегий для управления уровнем мочевой кислоты (МК) в крови. БАД могут служить важным дополнением к существующей лекарственной терапии, позволяя снизить уровень урикемии, частоту обострений артрита и улучшить качество жизни пациентов. Исследования показывают, что компоненты БАД могут модулировать воспалительные реакции и оказывать мочегонное действие, что особенно актуально для пациентов с уратной нефропатией. Однако, несмотря на обнадеживающие результаты, необходимы дальнейшие клинические испытания для подтверждения их безопасности и эффективности. Важно отметить, что интеграция БАД в стандартную терапию требует тщательного анализа взаимодействий с другими препаратами. Мы находимся на пороге новой эры в лечении подагры, и БАД могут занять достойное место в этой трансформации.
Об авторах
О. В. ЖелябинаРоссия
Ольга Владимировна Желябина, м. н. с.
лаборатория микрокристаллических артритов
Москва
М. С. Елисеев
Россия
Максим Сергеевич Елисеев, к. м. н., зав. лабораторией
лаборатория микрокристаллических артритов
Москва
Список литературы
1. Насонова В. А., Барскова В. Г. Ранние диагностика и лечение подагры – научно обоснованное требование улучшения трудового и жизненного прогноза больных. Научно-практическая ревматология. 2004; 1: 5–7. doi: 10.14412/1995-4484-2004-1374
2. Singh J. A., Gaffo A. Gout epidemiology and comorbidities. Semin Arthritis Rheum. 2020; 50 (3S): S 11–S 16. doi: 10.1016/j.semarthrit.2020.04.008
3. Елисеев М. С. Классификационные критерии подагры (рекомендации ACR/EULAR). Научно-практическая ревматология. 2015; 53 (6): 581–5. doi: 10.14412/1995-4484-2015-581-585
4. Chandratre P., Roddy E., Clarson L. et al. Health-related quality of life in gout : a systematic review. Rheumatology (Oxford). 2013; 52 (11): 2031–2040. doi: 10.1093/rheumatology/ket265
5. Чикина М. Н., Желябина О. В., Елисеев М. С. Влияние уратснижающей терапии на показатели качества жизни у пациентов с подагрой. Современная ревматология. 2021; 15 (3): 62–68. doi: 10.14412/1996-7012-2021-3-62-68
6. Елисеев М. С. Комментарии к обновленным рекомендациям Американской коллегии ревматологов по лечению подагры. Уратснижающие препараты (часть 1). Современная ревматология. 2020; 14 (3): 117–124. doi: 10.14412/1996-7012-2020-3-117-124
7. Yokose C., McCormick N., Choi H. K. Dietary and Lifestyle-Centered Approach in Gout Care and Prevention. Curr Rheumatol Rep. 2021; 23 (7): 51. Published 2021 Jul 1. doi: 10.1007/s11926–021–01020-y
8. Mahomoodally M. F., Coodian K., Hosenally M. et al. Herbal remedies in the management of hyperuricemia and gout: A review of in vitro, in vivo and clinical evidences. Phytother Res. 2024; 38 (7): 3370–3400. doi: 10.1002/ptr.8211
9. Chai S. C., Davis K., Zhang Z. et al. Effects of Tart Cherry Juice on Biomarkers of Inflammation and Oxidative Stress in Older Adults. Nutrients. 2019; 11 (2): 228. Published 2019 Jan 22. doi: 10.3390/nu11020228
10. Елисеев М. С., Желябина О. В. Влияние продуктов растительного происхождения на уровень мочевой кислоты : обзор литературы. Терапия. 2017; 4 (14): 52–58.
11. Andrés M., Sivera F., Buchbinder R. et al. Dietary supplements for chronic gout. Cochrane Database Syst Rev. 2021; 11 (11): CD 010156. Published 2021 Nov 12. doi: 10.1002/14651858.CD010156.pub3
12. Yang J., Li G., Xiong D., Chon T. Y., Bauer B. A. The Impact of Natural Product Dietary Supplements on Patients with Gout: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Evid Based Complement Alternat Med. 2020; 2020: 7976130. Published 2020 Jan 23. doi: 10.1155/2020/7976130
13. Hertzler SR, Lieblein-Boff JC, Weiler M, Allgeier C. Plant Proteins: Assessing Their Nutritional Quality and Effects on Health and Physical Function. Nutrients. 2020;12(12):3704. Published 2020 Nov 30. doi: 10.3390/nu12123704
14. Kumar A., Mosa K. A., Ji L. Y. et al. Metabolomics assisted biotechnological interventions for developing plant-based functional foods and nutraceuticals. Crit. Rev. Food. Sci. Nutr. 2018; 58: 1791–1807. doi: 10.1080/10408398.2017.1285752
15. Ji M. Y., Bo A., Yang M. et al. The pharmacological effects and health benefits of Platycodon grandiflorus – A medicine food homology species. Foods. 2020; 9: 142. doi: 10.3390/foods9020142
16. Gong X., Ji M. Y., Xu J. P. et al. Hypoglycemic effects of bioactive ingredients from medicine food homology and medicinal health food species used in China. Crit. Rev. Food Sci. Nutr. 2019: 1–24. doi: 10.1080/10408398.2019.1634517
17. Mehmood A., Zhao L., Wang C. T. et al. Management of hyperuricemia through dietary polyphenols as a natural medicament : A comprehensive review. Crit. Rev. Food Sci. 2019; 59: 1433–1455. doi: 10.1080/10408398.2017.1412939
18. Ji M. Y., Gong X., Li X. et al. Advanced research on the antioxidant activity and mechanism of polyphenols from Hippophae Species – A Review. Molecules. 2020; 25: 917. doi: 10.3390/molecules25040917
19. Chen L., Li M., Wu J. L. et al. Effect of lemon water soluble extract on hyperuricemia in mouse model. Food Funct. 2019; 10: 6000–6008. doi: 10.1039/C9FO00509A
20. Kapinova A., Stefanicka P., Kubatka P. et al. Are plant-based functional foods better choice against cancer than single phytochemicals? A critical review of current breast cancer research. Biomed. Pharmacother. 2017; 96: 1465–1477. doi: 10.1016/j.biopha.2017.11.134
21. Han S., Wei R. H., Han D. et al. Hypouricemic effects of extracts from Urtica hyperborea Jacq. ex Wedd. in hyperuricemia mice through XOD, URAT1, and OAT1. BioMed Res. Int. 2020; 2020: 1–8. doi: 10.1155/2020/2968135
22. Liu X. R., Huang S. S., Xu W. D. et al. Association of dietary patterns and hyperuricemia: A cross-sectional study of the Yi ethnic group in China. Food Nutr. Res. 2018; 62: 1380. doi: 10.29219/fnr.v62.1380
23. Li R. R., Yu K., Li C. W. Dietary factors and risk of gout and hyperuricemia : A meta-analysis and systematic review. Asia. Pac. J. Clin. Nutr. 2018; 27: 1344–1356. doi: 10.1007/s10067-013-2319-y
24. Ristic B., Sikder M. O.F., Bhutia Y. D., Ganapathy V. Pharmacologic inducers of the uric acid exporter ABCG2 as potential drugs for treatment of gouty arthritis. Asian J. Pharm. Sci. 2020; 15: 173–180. doi: 10.1016/j.ajps.2019.10.002
25. Xu L. Q., Shi Y. F., Zhuang S. G., Liu N. Recent advances on uric acid transporters. Oncotarget. 2017; 8: 100852–100862. doi: 10.18632/oncotarget.20135
26. Tan P. K., Liu S., Gunic E., Miner J. N. Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout. Sci. Rep. 2017; 7: 665. doi: 10.1038/s41598-017-00706-7
27. Jiang L. L., Gong X., Ji M. Y. et al. Bioactive Compounds from Plant-Based Functional Foods: A Promising Choice for the Prevention and Management of Hyperuricemia. Foods. 2020; 9 (8): 973. Published 2020 Jul 23. doi: 10.3390/foods9080973
28. Patra J. C., Chua B. H. Artificial neural network-based drug design for diabetes mellitus using flavonoids. J. Comput. Chem. 2011; 32: 555–567. doi: 10.1002/jcc.21641
29. Lin S. Y., Zhang G. W., Liao Y. J., Pan J. H. Dietary flavonoids as xanthine oxidase inhibitors: Structure-Affinity and Structure-Activity relationships. J. Agric. Food Chem. 2015; 63: 7784–7794. doi: 10.1021/acs.jafc.5b03386
30. Lin C. M., Chen C. S., Chen C. T. et al. Molecular modeling of flavonoids that inhibits xanthine oxidase. Biochem. Biophys. Res. Commun. 2002; 294: 167–172. doi: 10.1016/S0006-291X(02)00442-4
31. Cheng L. C., Murugaiyah V., Chan K. L. Flavonoids and phenylethanoid glycosides from Lippia nodiflora as promising antihyperuricemic agents and elucidation of their mechanism of action. J. Ethnopharmacol. 2015; 176: 485–493. doi: 10.1016/j.jep.2015.11.025
32. Montoro P., Braca A., Pizza C., De Tommasi N. Structure-antioxidant activity relationships of flavonoids isolated from different plant species. Food Chem. 2005; 92: 349–355. doi: 10.1016/j.foodchem.2004.07.028
33. Wang C. P., Wang X., Zhang X. et al. Morin improves urate excretion and kidney function through regulation of renal organic ion transporters in hyperuricemic mice. J. Pharm. Pharm. Sci. 2010; 13: 411–427. doi: 10.18433/J3Q30H
34. Subawa I. W., Astawa P., Bakta I. M. et al. Purple sweet potato (Ipomoea batatas L.) extract effects on levels of inflammatory markers and chondrocyte count in gout arthritis Wistar rat model. Foot Ankle Surg. 2023; 29 (8): 611–615. doi: 10.1016/j.fas.2023.07.007
35. Irondi E. A., Agboola S. O., Oboh G. et al. Guava leaves polyphenolics-rich extract inhibits vital enzymes implicated in gout and hypertension in vitro. J. Intercult. Ethnopharm. 2016; 5: 122–130. doi: 10.5455/jice.20160321115402
36. González-Castejón M., Rodriguez-Casado A. Dietary phytochemicals and their potential effects on obesity : A review. Pharmacol. Res. 2011; 64: 438–455. doi: 10.1016/j.phrs.2011.07.004
37. Sang M. M., Du G. Y., Hao J. et al. Modeling and optimizing inhibitory activities of Nelumbinis folium extract on xanthine oxidase using response surface methodology. J. Pharm. Biomed. 2017; 139: 37–43. doi: 10.1016/j.jpba.2017.02.048
38. Wang M. X., Liu Y. L., Yang Y. et al. Nuciferine restores potassium oxonate-induced hyperuricemia and kidney inflammation in mice. Eur. J. Pharmacol. 2015; 747: 59–70. doi: 10.1016/j.ejphar.2014.11.035
39. Tao Z. Y., Cheng Y., Tang Y. et al. Effect of evodiamine on the animal model of Hyperuricemia. Pharm. Clin. Chin. Mater. Med. 2014; 5: 69–71.
40. Song Y., Li J., Cheng Y. et al. Lowering effect of evodiamine dispersible tablets on uric acid in chickens. Chin. J. New Drugs. 2015; 24: 1057–1060.
41. Li P., Song Z. B., Chen M. M. et al. Research progress of therapeutic drug of hyperuricemia and its action target. China Mod. Med. 2018; 25: 16–19.
42. Gong L. X., Chi J. W., Wang J. et al. Research progress on main functional component and action mechanism of Dioscorea opposita. Sci. Technol. Food Ind. 2019; 40: 312–319. doi: 10.13386/j.issn1002-0306.2019.16.052
43. Su J. X., Wei Y. H., Liu M. L. et al. Anti-hyperuricemic and nephroprotective effects of Rhizoma Dioscoreae septemlobae extracts and its main component dioscin via regulation of mOAT1, mURAT1 and mOCT2 in hypertensive mice. Arch. Pharm. Res. 2014; 37: 1336–1344. doi: 10.1007/s12272-014-0413-6
44. Shi S., Wang N., Shang X. Y. et al. Effect of gypenoside on serum uric acid of hyperuricemic rats. Nat. Prod. Res. Dev. 2014; 26. doi: 10.16333/j.1001-6880.2014.08.028
45. Yang Q., Wang Q., Deng W. et al. Anti-hyperuricemic and anti-gouty arthritis activities of polysaccharide purified from Lonicera japonica in model rats. Int J. Biol. Macromol. 2019; 123: 801–809. doi: 10.1016/j.ijbiomac.2018.11.077/
46. Zhou J., Sun C., Li F. Research advances in mechanism of active components of traditional Chinese medicine for reducing uric acid. Chin. Pharmacol. Bull. 2018; 34: 19–22. doi: 10.3969/j.issn.1001-1978.2018.01.006
47. Zeng J. X., Xu B. B., Wang J. et al. Hypouricemic effects of acteoside and isoacteoside from Plantaginis Semen on mice with acute hyperuricemia and their possible mechanisms. Chin. Tradit. Pat. Med. 2016; 38: 1449–1454. doi: 10.3969/j.issn.1001-1528.2016.07.003
48. Brzezińska O., Styrzyński F., Makowska J., Walczak K. Role of Vitamin C in Prophylaxis and Treatment of Gout-A Literature Review. Nutrients. 2021; 13 (2): 701. Published 2021 Feb 22. doi: 10.3390/nu13020701
49. Juraschek S. P., Gaziano J. M., Glynn R. J. et al. Effects of vitamin C supplementation on gout risk: results from the Physicians' Health Study II trial. Am. J. Clin. Nutr. 2022; 116 (3): 812–819. doi: 10.1093/ajcn/nqac140
50. Xie K. L., Li Z. H., Dong X. Z., Gong M. X. Research progress of quercetin on inhibiting the activity of xanthine oxidase. Lishizhen Med. Mater. Med. Res. 2019; 30: 2223-2225. doi: 10.3969/j.issn.1008-0805.2019.09.060
51. Shi Y. L., Williamson G. Quercetin lowers plasma uric acid in pre-hyperuricaemic males: A randomised, double-blinded, placebo-controlled, cross-over trial. Brit. J. Nutr. 2016; 115: 800–806. doi: 10.1017/S0007114515005310
52. Feng W., Zhong X. Q., Zheng X. X. et al. Study on the effect and mechanism of quercetin in treating gout arthritis. Int Immunopharmacol. 2022; 111: 109112. doi: 10.1016/j.intimp.2022.109112
53. Ruiz-Miyazawa K.W., Staurengo-Ferrari L., Mizokami S. S. et al. Quercetin inhibits gout arthritis in mice: induction of an opioid-dependent regulation of inflammasome. Inflammopharmacology. Published online May 15, 2017. doi: 10.1007/s10787-017-0356-x
54. Jafari-Nozad A.M., Jafari A., Yousefi S. et al. Anti-gout and Urate-lowering Potentials of Curcumin : A Review from Bench to Beside. Curr Med Chem. 2024; 31 (24): 3715–3732. doi: 10.2174/0929867331666230721154653
55. McMullen M. K. Curcumin/Turmeric: Their Effect on Serum Uric Acid Remains Unknown. J. Diet. Suppl. 2021; 18 (6): 714–715. doi: 10.1080/19390211.2020.1811827
56. Wang C., Sun W., Dalbeth N. et al. Efficacy and safety of tart cherry supplementary citrate mixture on gout patients: a prospective, randomized, controlled study. Arthritis Res Ther. 2023; 25 (1): 164. Published 2023 Sep 7. doi: 10.1186/s13075-023-03152-1
57. Evidence reviews for diet and lifestyle modifications for managing gout: Gout: diagnosis and management. London: National Institute for Health and Care Excellence (NICE); June 2022.
58. Zhang M., Zhang Y., Terkeltaub R. et al. Effect of Dietary and Supplemental Omega-3 Polyunsaturated Fatty Acids on Risk of Recurrent Gout Flares. Arthritis Rheumatol. 2019; 71 (9): 1580–1586. doi: 10.1002/art.40896
59. Mason R. P., Sherratt S. C.R., Eckel R. H. Omega-3-fatty acids: Do they prevent cardiovascular disease? Best Pract Res Clin Endocrinol Metab. 2023; 37 (3): 101681. doi: 10.1016/j.beem.2022.101681
60. Чабан Н. Г., Степанов А. Е., Рапопорт Л. М. и др. Фитохимические основы создания препаратов для литолиза оксалатных камней. Тонкие химические технологии. 2014; 9 (2): 37–45.
61. Teixeira C. C., Cabral T. P., de Sousa J. P. et al. Study of Quality Assurance for Peumus Boldus M Products By Botanic Profiling, Extraction Optimization, HPLC Quantification And Antioxidant Assay. Pharmacognosy Journal 8 (3): 264–272. doi: 10.5530/pj.2016.3.16
62. Vinholes J., Grosso C., Andrade P. B. et al. In vitro studies to assess the antidiabetic, anti-cholinesterase and antioxidant potential of Spergularia rubra. Food Chem. 2011; 129 (2): 454–462. doi: 10.1016/j.foodchem.2011.04.098
63. Liu Z., Kong H., Zhang B. Narrative literature review of antidiabetic drugs' effect on hyperuricemia: elaborating actual data and mechanisms. Endocr Connect. 2024; 13 (6): e240070. doi: 10.1530/EC-24–0070
64. Wolfram R. M., Kritz H., Efthimiou Y., Stomatopoulos J., Sinzinger H. Effect of prickly pear (Opuntia robusta) on glucose- and lipid-metabolism in non-diabetics with hyperlipidemia-a pilot study. Wien Klin Wochenschr. 2002; 114 (19–20): 840–846.
65. Villar A., Recio M. C., Ríos J. L., Zafra-Polo M. C. Antimicrobial activity of essential oils from Sideritis species. Pharmazie. 1986; 41 (4): 298–299.
66. Ruiz-Navajas Y., Viuda-Martos M., Sendra E., Perez-Alvarez J.A., Fernández-López J. In vitro antioxidant and antifungal properties of essential oils obtained from aromatic herbs endemic to the southeast of Spain. J. Food Prot. 2013; 76 (7): 1218–1225. doi: 10.4315/0362–028X.JFP-12–554
67. Fareed S. A., Yousef E. M., Abd El-Moneam S. M. Assessment of Effects of Rosemary Essential Oil on the Kidney Pathology of Diabetic Adult Male Albino Rats. Cureus. 2023; 15 (3): e35736. doi: 10.7759/cureus.35736
68. Кароматов И. Д., Музаффаров Х. А. Мелисса лекарственная – химический состав, применение в древней, современной народной и научной медицине. Биология и интегративная медицина. 2021; 50 (3): 203–236.
69. Manjiri M. A., Asadpour A. A., Yousefi M. et al. The effects of Cynodon dactylon (Poaceae family) and Dolichos biflorus (Fabaceae family) extracts on decreasing size and excretion of kidney and urinary tract stones: a randomized, double-blind controlled trial. J. Complement Integr Med. 2022; 20 (1): 214–222. doi: 10.1515/jcim-2022-0166
70. Желябина О. В., Елисеев М. С., Кузьмина Я. И. Диета при подагре и гиперурикемии: несколько важных вопросов. Современная ревматология. 2024; 18 (1): 117–121. doi: 10.14412/1996-7012-2024-1-117-121
Рецензия
Для цитирования:
Желябина О.В., Елисеев М.С. Биологически активные добавки при подагре: возможности и перспективы. Медицинский алфавит. 2024;(29):13-18. https://doi.org/10.33667/2078-5631-2024-29-13-18
For citation:
Shelyabina O.V., Eliseev M.S. Biologically active additives in gout: opportunities and perspectives. Medical alphabet. 2024;(29):13-18. (In Russ.) https://doi.org/10.33667/2078-5631-2024-29-13-18